【科技前瞻】Nat Med:干细胞移植有望治疗多发性硬化症
多发性硬化症(Multiple Sclerosis,MS)是一种由于免疫系统异常识别和攻击,导致神经脱髓鞘的神经退行性疾病。MS累及视神经、脊髓、脑干、脑室周围白质等部位,表现为视力异常、肢体运动障碍和共济失调等,随着病情进展,患者将丧失身体的感觉和功能。针对MS已开发多种治疗策略,但其仅能起到缓解,无法治愈。神经干/祖细胞(NPC)是具有自我更新的多能细胞,有丝分裂活跃,能够分化为成熟脑细胞,减少髓鞘丢失、星形胶质细胞增生和轴突损失,并发挥营养支持和抗炎作用。研究证实,人类胎儿中枢神经系统的NPC是理想的神经移植治疗细胞系,其治疗特性已在非人灵长类实验中得到证实。近日,研究人员公布了一项评估人类胎儿中枢神经系统的神经干细胞/前体细胞移植在进行性MS患者中的安全性的I期临床试验结果。相关研究结果发表在Nature Medicine上。

研究人员采集了来自10-12周流产胎儿捐赠的胚胎干细胞,向12名出现严重症状甚至已经卧床不起的多发性硬化症患者直接进行脊柱注射。每位患者通过腰椎穿刺取得脊髓液样本用于测量多发性硬化症标志物包括神经保护和抗炎分子水平;此外患者还进行了核磁共振扫描测量MS进展重要参数——大脑灰质体积。治疗后三个月,患者再次接受腰椎穿刺,脊髓液样本显示神经保护和抗炎分子水平升高。注射两年后,患者进行核磁共振扫描,接受胚胎干细胞注射量最多的患者大脑灰质损失最少。综上,该研究首次开展了胚胎干细胞移植治疗MS的安全性实验,期待在不久的将来胚胎干细胞移植缓解MS患者症状和疾病进展得到证实。推荐阅
原文:Neural stem cell transplantation in patients with progressive multiple sclerosis: an open-label, phase 1 study.
Innovative pro-regenerative treatment strategies for progressive multiple sclerosis (PMS), combining neuroprotection and immunomodulation, represent an unmet need. Neural precursor cells (NPCs) transplanted in animal models of multiple sclerosis have shown preclinical efficacy by promoting neuroprotection and remyelination by releasing molecules sustaining trophic support and neural plasticity. Here we present the results of STEMS, a prospective, therapeutic exploratory, non-randomized, open-label, single-dose-finding phase 1 clinical trial ( NCT03269071 , EudraCT 2016-002020-86), performed at San Raffaele Hospital in Milan, Italy, evaluating the feasibility, safety and tolerability of intrathecally transplanted human fetal NPCs (hfNPCs) in 12 patients with PMS (with evidence of disease progression, Expanded Disability Status Scale ≥6.5, age 18-55 years, disease duration 2-20 years, without any alternative approved therapy). The safety primary outcome was reached, with no severe adverse reactions related to hfNPCs at 2-year follow-up, clearly demonstrating that hfNPC therapy in PMS is feasible, safe and tolerable. Exploratory secondary analyses showed a lower rate of brain atrophy in patients receiving the highest dosage of hfNPCs and increased cerebrospinal fluid levels of anti-inflammatory and neuroprotective molecules. Although preliminary, these results support the rationale and value of future clinical studies with the highest dose of hfNPCs in a larger cohort of patients.